Attention Deficit/Hyperactivity Disorder, Bipolar Disorder
Conditions
Brief summary
ADHD in the adult population is associated with several measures of harmful dysfunction. For example, adult ADHD is associated with high rates of separation/divorce and never-married status, lower educational attainment and occupational achievement, absenteeism, presenteeism, and job termination, as well as decreased social function. Individuals with adult ADHD are more likely than controls to have a comorbid diagnosis of bipolar disorder, alcohol and substance abuse, as well as antisocial personality disorder. Psychostimulants are the most frequently employed medications in the treatment of adult ADHD. Several psychostimulants are Health Canada and US FDA-approved for the treatment of ADHD symptoms in adulthood. Hitherto, no trial has evaluated the safety and efficacy of a psychostimulant in the treatment of ADHD symptomatology in adult individuals with bipolar disorder. Vyvanse is the first prodrug stimulant indicated for the treatment of adult (and pediatric) ADHD. Vyvanse is a therapeutically inactive molecule (i.e. prodrug). After oral ingestion, lisdexamfetamine is converted to l-lysine, a naturally occurring essential amino acid, and active d-amphetamine, which is responsible for the drug's activity. Vyvanse provides a longer duration of effect consistent throughout the day with reduced potential for risk of abuse. Vyvanse is generally well tolerated with an adverse event profile similar to other psychostimulant medications. Available evidence indicates that in most treated subjects, Vyvanse is weight-neutral and/or is associated with weight loss. Moreover, in some individuals, it is associated with improvement in both glucose and lipid homeostasis. The evaluation of safety/tolerability profiles as well as the effectiveness of lisdexamfetamine in a real-world population has significant translational value.
Interventions
DRUGlisdexamfetamine dimesylate
Dosage form: Capsules; Dosage strength: 30-70mg/day, flexible dosing; Duration: 4 weeks
Sponsors
Shire
University Health Network, Toronto
Study design
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
No
Inclusion criteria
* Outpatient status * Male or female subjects between the ages of 18 to 55 years, inclusive * Primary diagnosis of Bipolar Disorder and ADHD according to criteria in the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) using the Mini International Neuropsychiatric Interview. * Agree to use reliable method of birth control * YMRS score \</= 12 * CGI-BP \< 6 * Able and willing to provide a written informed consent
Exclusion criteria
* Current Axis I primary psychiatric diagnosis other than Bipolar Disorder and ADHD * Current Axis II psychiatric disorder of primary clinical focus * Active alcohol as well as illicit or other substance abuse during the past 3 months * Current clinically unstable medical condition. * Inability to understand and engage in the process of informed consent. * Inability to cooperate with study procedures. * Presence of known allergies or hypersensitivity to lisdexamfetamine * History of destabilization when exposed to psychostimulant medication * Current high risk of suicide * Current treatment with corticosteroids * Electroconvulsive therapy in the last 1 year * Current participation in a separate clinical research study involving an investigational drug
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Metabolic parameters | Screening (Week -1) to Endpoint (Week 4); Completed weekly on all 6 visits | Weight; BMI; Waist circumference |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| CAARS | Baseline (Week 0) to Endpoint (Week 4); completed weekly on 5 visits | Measure of ADHD symptoms |
| CGI-BP | Baseline (Week 0) to Endpoint (Week 4); Completed weekly on all 6 visits | — |
| ADHD-RS | Baseline (Week 0) to Endpoint (Week 4); completed weekly on 5 visits | Measure of ADHD symptoms |
| AAQoL | Baseline (Week 0), Week 2, Endpoint (Week 4); Completed on 3 visits | Quality of Life |
| Metabolic Peptidergic systems | Baseline (Week 0) and Endpoint (Week 4); Completed on 2 visits | Insulin; Resistin; Ghrelin; Leptin; Adiponectin |
| Q-LES-Q | Baseline (Week 0) and Endpoint (Week 4); Completed on 2 visits | Quality of Life |
Countries
Canada
Outcome results
None listed